Zhejiang Cancer Hospital and Peking University researchers identified a stomach cancer biomarker intended to predict which patients are likely to benefit from neoadjuvant immunotherapy. The report describes high accuracy in identifying responders, setting up the potential for more targeted patient selection in gastric cancer treatment pathways.